Our pipeline

Our pipeline is built on a unique strategy: simultaneous inhibition of a primary drug target and its compensatory mechanism. This approach increases the response rates and reduces the risk of resistance.

Product

Program

Indication

Discovery

Preclinical

Phase 1

Phase 2

Licensor

GORD208

Dual PRMTs Inhibitor

MTAP deleted tumors

Licenced to Kohde Pharma

GORD132

MET- BiAb

MET amplified

In house

GORD167

Undisclosed BiAb

PD-L1 non-responders

In house